Quantifying hope: An EU perspective of rare disease therapeutic space and market dynamics

Emmanuelle Cacoub,Nathalie Barreto Lefebvre,Dimitrije Milunov,Manish Sarkar,Soham Saha
DOI: https://doi.org/10.1101/2024.07.21.24310776
2024-08-01
Abstract:Rare diseases, affecting millions globally, pose a significant healthcare burden despite impacting a small population. While most are genetic and often begin in childhood, diagnosis remains slow and only 5% have approved treatments. The UN emphasizes improved access to primary care for these patients and their families. Whole-genome sequencing (WGS) and next-generation sequencing (NGS) offer hope for earlier and more accurate diagnoses, potentially leading to preventative measures and targeted therapies. This study explores the therapeutic landscape for rare diseases, analyzing drugs in development by 176 companies and those already approved by the European Medicines Agency (EMA). We differentiate between orphan drugs with market exclusivity and repurposed existing drugs, both crucial for patients. By analyzing market size, segmentation, and publicly available data, this comprehensive study aims to pave the way for improved treatments and a brighter future for rare disease patients.
What problem does this paper attempt to address?